BIOAGE LABS, INC. (BIOA) Quick Ratio
- Quick ratio · latest quarter: Value 16.62×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 16.62× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $319.37M ÷ $19.22M ≈ 16.62× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 319.37M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 19.22M USD | Liabilities, Current |
| Cash and equivalents | 73.96M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 244.78M USD | Marketable Securities, Current |
| Customer receivables | 625.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $319.37M | $19.22M | $73.96M | $244.78M | $625.00K | (m) | 16.62× |
| 2026-03-31 | $383.90M | $15.83M | $241.78M | $141.42M | $709.00K | (m) | 24.26× |
| 2025-12-31 | $281.87M | $20.14M | $188.89M | $92.21M | $769.00K | (m) | 14.00× |
| 2025-09-30 | $286.29M | $24.49M | $215.57M | $70.20M | $515.00K | (m) | 11.69× |
| 2025-06-30 | $297.90M | $22.84M | $220.33M | $76.97M | $603.00K | (m) | 13.04× |
| 2025-03-31 | $320.88M | $23.74M | $257.49M | $63.03M | $361.00K | (m) | 13.52× |
| 2024-12-31 | (m) | $27.77M | $354.35M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $19.08M | $334.47M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $173.99M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $58.17M | $21.64M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |